Lawrence Berkeley National Laboratory
Recent Work

Title
Stereotactic Helium-Ion Radiosurgery for the Treatment of Intracranial Arteriovenous Malformations

Permalink
https://escholarship.org/uc/item/7gq51262

Authors
Fabrikant, J.I.
Levy, R.P.
Frankel, K.A.
et al.

Publication Date
1989-12-01
Stereotactic Helium-Ion Radiosurgery for the Treatment of Intracranial Arteriovenous Malformations


December 1989
DISCLAIMER

This document was prepared as an account of work sponsored by the United States Government. While this document is believed to contain correct information, neither the United States Government nor any agency thereof, nor the Regents of the University of California, nor any of their employees, makes any warranty, express or implied, or assumes any legal responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by its trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof, or the Regents of the University of California. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof or the Regents of the University of California.
STEREOTACTIC HELIUM-ION RADIOSURGERY FOR THE TREATMENT OF INTRACRANIAL ARTERIOVENOUS MALFORMATIONS


Research Medicine and Radiation Biophysics
Lawrence Berkeley Laboratory
1 Cyclotron Road
Berkeley, CA

Presented at the International Workshop on Proton and Narrow Photon Beam Therapy, Oulu, Finland, 8–10 June, 1989.

Research was supported by Office of Health and Environmental Research, U.S. Department of Energy Contract DE-AC03-76SF00098.
STEREOTACTIC HELIUM-ION RADIOSURGERY FOR THE TREATMENT OF INTRACRANIAL ARTERIOVENOUS MALFORMATIONS


Donner Laboratory and Donner Pavilion, Lawrence Berkeley Laboratory, University of California, Berkeley, CA 94720, U.S.A.

INTRODUCTION

One of the more challenging problems of vascular neurosurgery is the management of surgically-inaccessible arteriovenous malformations (AVMs) of the brain. At Lawrence Berkeley Laboratory, we have developed the method of stereotactic heavy-charged-particle (helium-ion) Bragg peak radiosurgery for treatment of inoperable intracranial AVMs in over 300 patients since 1980 [Fabrikant et al. 1989, Fabrikant et al. 1985, Levy et al. 1989]. This report describes patient selection, treatment method, clinical and neuroradiologic results and complications encountered.

METHOD

Prospective patients with surgically-inaccessible AVMs are considered to be candidates for stereotactic radiosurgery if they have a history of intracranial hemorrhage, nonhemorrhagic neurologic dysfunction, intractable vascular headaches or refractory seizures. The method of helium-ion radiosurgery has been described in detail previously [Fabrikant et al. 1989, Fabrikant et al. 1985, Levy et al. 1989]. A removable noninvasive thermoplastic mask, stereotactic frame, and integrated stereotactic patient positioner have been developed for patient immobilization and accurate stereotactic localization of the AVM [Lyman & Chong 1974, Lyman et al. 1989]. This system permits precise correlation and data transfer between sequential stereotactic cerebral angiography and stereotactic computerized tomography (CT) and magnetic resonance image (MRI) scans [Phillips et al. 1989a].

CT scan data are used to identify and compensate for inhomogeneities in the tissues traversed by the charged-particle beams and to calculate the dose distribution in each patient, using a VAX 11/780 computer system [Chen et al. 1979]. The

1Research supported by the Director, Office of Energy, Health and Environmental Research of the United States Department of Energy under Contract DE-AC03-76SF00098.
helium-ion beam is shaped by individually-fabricated apertures to conform precisely to the contours of the AVM and to any cross-section width from 4 to 80 mm. The range of the Bragg ionization peak and the width of the peak in the direction of the beam are determined by interposing appropriate absorbers in the beam path. Thus, each beam is tailored to place a three-dimensional high dose region of desired shape stereotactically within the brain. Multiple entry angles and beam ports are chosen so that the high-dose Bragg peak regions of the individual beams intersect within the AVM target [Levy et al. 1989].

The periphery of the AVM is enclosed by the 90% isodose contour. Dose fall-off to less than 10% of the maximum dose occurs within 4 to 6 mm of the target distally, and within 2 to 3 mm along the lateral margins of the helium-ion beam [Fabrikant et al. 1985]. Based on approved multi-institutional research protocols, maximum central (100%) doses of 45 GyE $^2$ were used initially, with larger AVMs or those in more sensitive regions receiving 35 to 40 GyE. Successful obliteration of AVMs at the lower end of this range led us to scale down doses in a stepwise fashion, to determine the lowest effective dose. Thus, subsequent patients were treated with 25 to 35 GyE. Currently, maximum central doses of 15 to 25 GyE are used, based on the size, shape and location of the AVM. Smaller or supratentorial AVMs are treated with higher doses than larger or brainstem lesions. Densely packed AVMs are treated with higher doses than those loosely intertwined with normal brain tissue. Treatment is given in 1 or 2 daily fractions, 3 to 5 ports per fraction. Lesions less than 4,000 mm$^3$ are generally treated in 1 d, larger lesions in 2 d. Each fraction requires less than 1 h of patient positioning and immobilization, mostly to verify positioning, and each port requires about 1 min of irradiation. A gradually tapering 2 wk course of low-dose dexamethasone is begun 1 d prior to treatment. All patients are treated on an ambulatory basis.

Patients are examined on a regular follow-up basis. Cerebral angiography is performed at 12-mo intervals until the AVM has been completely obliterated, or has stabilized. MRI scanning is performed at 6-mo intervals, in order to assess the vascular response and to identify early or delayed radiation injury and/or edema in the brain, and to guide appropriate management. Patients with angiographically-occult (cryptic) AVMs are followed by MRI scanning at 6-mo intervals; follow-up angiography is not performed.

RESULTS

Patient selection. We have thus far treated 316 patients (155 males, 161 females) aged 6 to 69 y; 45 patients were 18 y or younger. There were 148 patients with AVMs in the cerebral hemispheres, primarily involving eloquent regions of motor or speech function; 93 had AVMs in the thalamus, basal ganglia, internal capsule or corpus callosum; 42 had lesions in the brainstem; 21 had cerebellar malformations; 12 had

\[^2\text{GyE} = \text{Gy equivalent}. \text{ A relative biologic effectiveness (RBE) of 1.3 is assumed for the helium-ion Bragg peak.}\]
lesions of the vein of Galen, choroid plexus or other miscellaneous locations. There were 288 angiographically-demonstrable and 28 cryptic AVMs; volumes ranged from 80 mm$^3$ to 60,000 mm$^3$.

All patients were neurologically symptomatic. The most common presentation was intracranial hemorrhage; this occurred in 45% of patients. Other presenting manifestations included headaches (40%), seizures (23%), nonhemorrhagic neurologic dysfunction (20%), and hemorrhage from associated arterial aneurysms (5%). Many patients had some combination of these.

The majority of patients had no interventional therapy prior to stereotactic radiosurgery. Many patients had some form of AVM surgery (29%) and/or interventional neuroradiologic procedure (21%) before radiosurgery. Some patients had one or more adjunct procedures (e.g., arterial aneurysm repair (5%), shunt placement (4%), hematoma evacuation (2%)) not intended to result in any decrease in AVM size or blood flow. Various combinations of multiple therapeutic interventions were carried out in many patients before radiosurgery.

**Clinical results.** All patients completed the course of stereotactic neuroradiologic evaluation and treatment without difficulty. None required sedation or anesthesia during the radiosurgical treatment, although smaller children did receive general anesthesia during their diagnostic stereotactic cerebral angiograms.

Most patients (75%) have remained normal or improved to normal neurologic status following stereotactic radiosurgery; 15% have fixed neurologic deficits, unchanged from before treatment; 10% have worsened.

For complete obliteration, there is a relationship of dose and volume primarily, and location only secondarily. When the entire arterial phase of the AVM has been targeted for radiosurgery, the incidence of complete AVM obliteration 2 y post-treatment is: 90 to 95% for volumes ≤ 4,000 mm$^3$, 80 to 85% for volumes > 4,000 mm$^3$ and ≤ 14,000 mm$^3$, 65 to 70% for volumes > 14,000 mm$^3$. The total obliteration rate for all volumes up to 60,000 mm$^3$ is approximately 80%. When radiosurgery was limited to the earliest-filling arterial nidus, many patients had an incomplete response. In this subset of patients, we frequently observed complete obliteration of the radiosurgically-treated volume with an unchanged lesion periphery; this left undesirable shunts which require retreatment. Angiographic changes of progressive vascular obliteration have been observed to continue beyond 24 mo in a few cases. The interpretation of follow-up MRI scans for cryptic AVMs following radiosurgery is unresolved, and is the subject of continuing investigation in our laboratory.

Intracranial hemorrhage from a radiosurgically-treated AVM following radiosurgery occurred in 6.5% of patients; of these patients, 80% hemorrhaged within the first 14 mo after radiosurgery. A few patients hemorrhaged after treatment from previously unrecognized arterial aneurysms that had been hidden within the AVM.

**Complications.** Complications are scored very conservatively; any definite or possible sequelae of radiosurgery are considered to be complications, even if functional impairment is minimal or temporary. Some neurologic dysfunction occurred in 15% of patients, nearly all in the earlier high-dose group. More than half of these patients
have had complete or nearly complete return to their preradiosurgery condition. Moderate or severe symptomatic (reversible or irreversible) vasogenic edema has occurred in 8% of cases; symptomatic occlusion of normal vessels, 2 to 3%; permanent late delayed radiation injury, 1%. Overall serious and permanent neurologic complications have occurred within 2 y after treatment in approximately 5 to 6% of cases in the earlier high-dose group, but appear to be in the range of 2 to 3% at current lower doses. There has been no immediate treatment morbidity. No deaths have occurred from the radiation procedure.

DISCUSSION AND CONCLUSIONS

The physical characteristics of heavy-charged-particle beams are uniquely advantageous for the radiosurgical treatment of discrete and defined intracranial lesions [Phillips et al. 1989a]. Studies in this laboratory have demonstrated that the radiation dose with this method to normal brain structures adjacent to and remote from the AVM is relatively low, particularly when compared to photon irradiation techniques; this difference appears especially marked in the treatment of larger AVMs [Phillips et al. 1989b]. Bragg peak radiosurgery can be used with precision to treat eccentric and irregular AVMs of very large size, as well as to deliver extremely sharp focal beams accurately to small brainstem lesions. We consider the results in this series of more than 300 patients with high-risk deep AVMs to be favorable. Stereotactic heavy-charged-particle radiosurgery has successfully obliterated a majority of inoperable AVMs, including many much larger than appear to be amenable to current photon irradiation techniques, while effecting satisfactory protection of adjacent brain structures.

The complications encountered in this series, even though scored very conservatively, compare favorably with the potential risks of operative intervention of surgically-accessible AVMs or the spontaneous risk of progressive neurologic deficit in this patient group [Heros & Tu 1987]. The incidence of sequelae is not solely dose-dependent nor confined to the high-dose group. Delayed radiation sequelae may be manifested by enhanced vascular permeability and vasogenic edema. Such edema is usually asymptomatic and an incidental finding at follow-up MRI scanning; it can remain evident for up to 2 y and more, especially in the deep white matter, and then slowly regress to a normal or near-normal state. If edema is massive or present in sensitive and confined central brain structures, it may cause transient or permanent neurologic impairment. Prompt treatment with corticosteroids has frequently arrested or reversed this process and associated neurologic dysfunction. Irreversible neurologic damage can occur if the radiosurgical treatment induces occlusion of normal vessels and consequent focal infarction, especially in the central nuclei or brainstem [Levy et al. 1989]. Histologically-confirmed radiation necrosis in this series has been rare, limited to a few patients in the earlier higher-dose group; however, additional cases may have been classified as severe vasogenic edema.

Comparison of clinical results of different radiosurgical procedures and clinical series requires the establishment of common measurable parameters based on defined...
protocols. Confounding variables include patient selection criteria, AVM size and location, treatment dose, prior therapeutic intervention, duration of follow-up, and threshold for classification of complications. The optimal dose must be determined for radiosurgical treatment of AVMs in various locations within the brain, in order to improve the cure rate, protect against future intracranial hemorrhage and minimize potential adverse sequelae of the radiation treatment.
References


